Sign in
TerminatedPhase 1/2

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Key facts

Who runs it
Epizyme, Inc.
Where
Boston, Chattanooga, Denver, Hendersonville, Knoxville, Las Vegas, Nashville, New York, Pittsburgh, Port Saint Lucie, Rolling Meadows, San Antonio, San Diego, Syracuse, and The Bronx, United StatesSee the 16 sitesAlso in 2 other countries, 8 sites
Status
Terminated
Phase
Phase 1/2
People taking part
102 people enrolled
Started
18 Nov 2019
Ended
4 Nov 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tazemetostat
  • Abiraterone/prednisone
  • Enzalutamide
Record updated
10 March 2026
Why it stopped
The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age at the time of consent ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 (Appendix
  • Life expectancy of > 3 months
  • Histologically or cytologically confirmed adenocarcinoma of the prostate. Small cell or neuroendocrine tumors of the prostate are also permitted
  • Progressive disease in the setting of medical or surgical castration (ie, castration- resistant prostate cancer [CRPC]) by PCWG3 criteria for study entry; Evidence of disease progression by rising PSA or; Soft tissue progression per RECIST 1.1 or; Evidence of disease progression by observation of 2 new bone lesions since the initiation of last systemic therapy
  • Metastatic prostate cancer disease, documented by the following imaging; Bone lesions on bone scan (per PCWG3) or by soft tissue disease (per RECIST 1.1) by CT/MRI imaging Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist
  • Prior treatment with a second-generation androgen inhibitor as follows:; For phase 1b, EITHER Previously untreated with or progressed on a second generation androgen inhibitor (abiraterone, enzalutamide, or apalutamide) OR progressed on a second generation inhibitor (inhibitor (abiraterone, enzalutamide, or apalutamide); For phase 2 randomized component (i.e, enzalutamide- containing treatment arms) of the study, previously progressed on abiraterone

Who cannot take part

  • Treatment with any of the following for prostate cancer within the indicated timeframe prior to day 1 of starting study treatment:; First generation: AR antagonists (eg, bicalutamide, nilutamide, flutamide) within 4 weeks; 5-alpha-reductase inhibitors, ketoconazole, estrogens (including diethylstilbesterol), or progesterones within 2 weeks; Chemotherapy (except as permitted in inclusion criteria #10) within 3 weeks; Prior radionuclide therapy within 4 weeks; Another interventional product or standard agent in a clinical study within 28 days prior to the first planned dose of Tazemetostat; For phase 2 subjects to be randomized to one of the enzalutamide treatment arms only, prior treatment with the second-generation androgen antagonist including enzalutamide, apalutamide, darolutamide, and proxalutamide, etc
  • Severe concurrent disease, infection, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for enrollment
  • Has had prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2
  • Known symptomatic brain metastases

Where in United States

Also in 2 other countries, 8 sites

  • Beth Israel Deaconess Medical CenterBoston, United States
  • Dana-Farber Cancer InstituteBoston, United States
  • SCRI Tennessee Oncology ChattanoogaChattanooga, United States
  • The Urology Center of ColoradoDenver, United States
  • Urology Associates P.C.Hendersonville, United States
  • XCancer - Tennesee Cancer SpecialistsKnoxville, United States
  • Comprehensive Cancer Centers of Nevada - Central ValleyLas Vegas, United States
  • SCRI Tennessee Oncology - NashvilleNashville, United States
  • Memorial Sloan-Kettering Cancer CenterNew York, United States
  • University of Pittsburgh Medical Center - Hillman Cancer CenterPittsburgh, United States
  • Hematology - Oncology Associates of the Treasure CoastPort Saint Lucie, United States
  • XCancer - Northwest Oncology and HematologyRolling Meadows, United States
  • Urology San AntonioSan Antonio, United States
  • Genesis Healthcare PartnersSan Diego, United States
  • Associated Medical Professionals of NY, PLLC - UrologySyracuse, United States
  • Montefiore Einstein Center for Cancer CareThe Bronx, United States

About the trial

What the trial wants to find out

This is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with enzalutamide or abiraterone/prednisone (phase 1b) versus enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate cancer (mCRPC) who have progressed on either abiraterone acetate, enzalutamide, or apalutamide or who are second generation anti-androgen treatment naive, and who have not received chemotherapy for mCRPC.

Read full original descriptionShow less

This study is designed to determine the recommended phase 2 doses (RP2D) of tazemetostat in combination with either enzalutamide or abiraterone/prednisone, based on safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy profiles.

The 4 groups in the trial

  • Phase 1b: Tazemetostat in Combination with Abiraterone/PrednisoneTreatment being tested

    In Phase 1b, abiraterone/prednisone will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity

    Treatment: Tazemetostat and Abiraterone/prednisone

  • Phase 1b: Tazemetostat in Combination with EnzalutamideTreatment being tested

    In Phase 1b, enzalutamide will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity

    Treatment: Tazemetostat and Enzalutamide

  • Phase 2: Tazemetostat in Combination with EnzalutamideTreatment being tested

    Participants will receive the newly established recommended phase 2 dose, orally twice daily when given in combination with enzalutamide) as determined in phase 1b part of the study) or enzalutamide alone. All participants will receive treatment in 28-day cycles.

    Treatment: Tazemetostat and Enzalutamide

  • Phase 2: Enzalutamide onlyExisting treatment, for comparison

    In Phase 2, Enzalutamide will be administered on cycle 1 day 1

    Treatment: Enzalutamide

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Record updated
10 March 2026